Please Wait.....

Report

Global Stroke Market

Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research

The global stroke market is expected to reach USD 58.93 billion by 2032 from USD 33.00 billion in 2024, growing at a substantial CAGR of 7.8% in the forecast period of 2025 to 2032.
Market Segmentation:
Global Stroke Market, By Type (Ischemic Stroke, Hemorrhage Stroke, and Transient Ischemic Attack (TIA)), Diagnosis & Treatment (Treatment and Diagnosis), Gender (Female and Male), End User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories, and Others), Distribution Channel (Direct, Retail, and Online), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Austria, Ireland, Norway, Poland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Taiwan, rest of Asia-Pacific, Brazil, Argentina, Chile, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and rest of Middle East and Africa) - Industry Trends & Forecast To 2032
Overview of the Global Stroke Market Dynamics:
Drivers
- Rising incidences of stroke drive demand for treatments
- Increasing number of patients with hypertension and coronary heart diseases
Restraints
- High cost of diagnosis
- Increase in product recalls
Opportunities
- High cost of diagnosis
- Increase in product recalls
Market Players:
The key market players for global stroke market are listed below:
- Bristol-Myers Squibb Company
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd
- DAIICHI SANKYO COMPANY, LIMITED
- Sanofi
- Johnson & Johnson Services, Inc.
- Bayer AG
- Sandoz AG
- Pfizer Inc.
- Medtronic
- Abbott
- Viatris Inc.
- AstraZeneca
- Penumbra, Inc.
- GLENMARK PHARMACEUTICALS LTD
- Fresenius SE & Co. KGaA
- Teva Pharmaceuticals USA, Inc.
- Lupin
- Amneal Pharmaceuticals LLC

TABLE OF CONTENTS
1 INTRODUCTION 77
1.1 OBJECTIVES OF THE STUDY 77
1.2 MARKET DEFINITION 77
1.3 LIMITATIONS 79
1.4 MARKETS COVERED 79
2 MARKET SEGMENTATION 84
2.1 MARKETS COVERED 84
2.2 GEOGRAPHICAL SCOPE 85
2.3 YEARS CONSIDERED FOR THE STUDY 86
2.4 CURRENCY AND PRICING 86
2.5 DBMR TRIPOD DATA VALIDATION MODEL 87
2.6 MULTIVARIATE MODELLING 90
2.7 TYPE LIFELINE CURVE 90
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 91
2.9 DBMR MARKET POSITION GRID 92
2.10 MARKET END USER COVERAGE GRID 93
2.11 VENDOR SHARE ANALYSIS 94
2.12 SECONDARY SOURCES 95
2.13 ASSUMPTIONS 95
3 EXECUTIVE SUMMARY 96
4 PREMIUM INSIGHTS 98
4.1 PESTEL ANALYSIS 103
4.2 PORTER'S FIVE FORCES 104
5 GLOBAL STROKE MARKET, REGULATORY FRAMEWORK 105
5.1 REGULATION IN U.S. 105
5.2 REGULATION IN EUROPE 106
5.3 REGULATION IN CHINA 107
5.4 REGULATION IN JAPAN 107
5.5 REGULATION IN SOUTH AFRICA 108
6 MARKET OVERVIEW 109
6.1 DRIVERS 111
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS 111
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 112
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS 113
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES 113
6.2 RESTRAINTS 115
6.2.1 HIGH COST OF DIAGNOSIS 115
6.2.2 INCREASE IN PRODUCT RECALL 115
6.3 OPPORTUNITIES 117
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES 117
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES 117
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT 118
6.4 CHALLENGES 119
6.4.1 FALSE DIAGNOSIS IN STROKES 119
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE 120
7 GLOBAL STROKE MARKET, BY TYPE 121
7.1 OVERVIEW 122
7.2 ISCHEMIC STROKE 125
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 126
7.2.2 EMBOLIC (CEREBRAL EMBOLISM) 126
7.3 HEMORRHAGIC STROKE 127
7.3.1 SUBARACHNOID HEMORRHAGE 127
7.3.2 INTRACEREBRAL HEMORRHAGE 127
7.4 TRANSIENT ISCHEMIC ATTACT (TIA) 128
8 GLOBAL STROKE MARKET, BY GENDER 129
8.1 OVERVIEW 130
8.2 FEMALE 133
8.3 MALE 134
9 GLOBAL STROKE MARKET, BY DIAGNOSIS AND TREATMENT 135
9.1 OVERVIEW 136
9.2 TREATMENT 139
9.2.1 BY TREATMENT TYPE 140
9.2.1.1 MEDICATION 140
9.2.1.1.1 MEDICATION, BY CLASS 140
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES 141
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 142
9.2.1.1.1.1.2 RAMIPRIL 142
9.2.1.1.1.1.3 LISINOPRIL 142
9.2.1.1.1.1.4 ENALAPRIL 142
9.2.1.1.1.1.5 PERINDOPRIL 142
9.2.1.1.1.1.6 OTHER 142
9.2.1.1.1.2 THIAZIDE DIURETICS 143
9.2.1.1.1.2.1 INDAPAMIDE 143
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE 143
9.2.1.1.1.2.3 SPIRONOLACTONE 143
9.2.1.1.1.2.4 AMILORIDE 143
9.2.1.1.1.2.5 OTHER 143
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS 144
9.2.1.1.1.3.1 AMLODIPINE 144
9.2.1.1.1.3.2 NIFEDIPINE 144
9.2.1.1.1.3.3 VERAPAMIL 144
9.2.1.1.1.3.4 NICARDIPINE 144
9.2.1.1.1.3.5 FELODIPINE 144
9.2.1.1.1.3.6 NIMODIPINE 144
9.2.1.1.1.3.7 OTHERS 144
9.2.1.1.1.4 BETA BLOCKERS 145
9.2.1.1.1.4.1 ATENOLOL 145
9.2.1.1.1.4.2 BISOPROLOL 145
9.2.1.1.1.4.3 LABETOLOL 145
9.2.1.1.1.4.4 OTHERS 145
9.2.1.1.1.5 ALPHA-BLOCKERS 146
9.2.1.1.1.5.1 DOXAZOSIN 146
9.2.1.1.1.5.2 OTHERS 146
9.2.1.1.1.6 OTHERS 146
9.2.1.1.1.7 ANTIPLATELET DRUGS 147
9.2.1.1.1.7.1 ASPIRIN 147
9.2.1.1.1.7.2 CLOPIDOGREL 147
9.2.1.1.1.7.3 DIPYRIDAMOLE 147
9.2.1.1.1.7.4 TICLOPIDINE 147
9.2.1.1.1.7.5 OTHERS 147
9.2.1.1.1.8 ANTICOAGULANTS 148
9.2.1.1.1.8.1 WARFARIN 148
9.2.1.1.1.8.2 APIXABAN 148
9.2.1.1.1.8.3 DABIGATRAN 148
9.2.1.1.1.8.4 HEPARIN 148
9.2.1.1.1.8.5 RIVAROXABAN 148
9.2.1.1.1.8.6 OTHERS 148
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA) 149
9.2.1.1.1.9.1 ALTEPLASE 149
9.2.1.1.1.9.2 TENECTEPLASE 149
9.2.1.1.1.9.3 RETEPLASE 149
9.2.1.1.1.9.4 ANISTREPLASE 149
9.2.1.1.1.9.5 OTHERS 149
9.2.1.1.1.10 STATINS 150
9.2.1.1.1.10.1.1 ATORVASTATIN 151
9.2.1.1.1.10.1.2 SIMVASTATIN 151
9.2.1.1.1.10.1.3 LOVASTATIN 151
9.2.1.1.1.10.1.4 ROSUVASTATIN 151
9.2.1.1.1.10.1.5 FLUVASTATIN 151
9.2.1.1.1.10.1.6 PRAVASTATIN 151
9.2.1.1.1.10.1.7 PITAVASTATIN 151
9.2.1.1.1.10.1.8 OTHERS 151
9.2.1.1.1.11 VITAMIN K 152
9.2.1.1.1.12 SUPPORTIVE MEDICATION 152
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS 152
9.2.1.1.1.12.2 ANTIPYRETICS 152
9.2.1.1.1.12.3 OTHERS 152
9.2.1.1.2 MEDICATION, BY DRUG TYPE 153
9.2.1.1.2.1 BRANDED 153
9.2.1.1.2.1.1 ACTIVASE 154
9.2.1.1.2.1.2 EDOBAXAN 154
9.2.1.1.2.1.3 COUMADIN 154
9.2.1.1.2.1.4 HEPARIN LEO 154
9.2.1.1.2.1.5 DUOPLAVIN 154
9.2.1.1.2.1.6 AGGRENOX 154
9.2.1.1.2.1.7 RETAVASE 154
9.2.1.1.2.1.8 JANTOVEN 154
9.2.1.1.2.1.9 CATHFLO 154
9.2.1.1.2.1.10 OTHER 154
9.2.1.1.2.2 GENERIC 154
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION 155
9.2.1.1.3.1 ORAL 155
9.2.1.1.3.1.1 TABLET 155
9.2.1.1.3.1.2 CAPSULES 155
9.2.1.1.3.1.3 OTHERS 155
9.2.1.1.3.2 PARENTERAL 156
9.2.1.1.3.2.1 INTRAVENOUS 156
9.2.1.1.3.2.2 SUBCUTANEOUS 156
9.2.1.1.3.3 OTHERS 156
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE 157
9.2.1.1.4.1 PRESCRIPTION 157
9.2.1.1.4.2 OVER THE COUNTER (OTC) 157
9.2.1.1.5 MEDICATION, BY THERAPY TYPE 157
9.2.1.1.5.1 COMBINATION THERAPY 157
9.2.1.1.5.2 MONOTHERAPY 157
9.2.1.2 SURGERY 158
9.2.1.2.1 EMBOLIC COILS 158
9.2.1.2.2 ASPIRATION CATHETERS 158
9.2.1.2.3 STENT RETRIEVER 158
9.2.1.2.4 SURGICAL CLIPPING 158
9.2.1.2.5 OTHERS 158
9.2.1.3 OTHERS THERAPY 159
9.2.1.3.1 PHYSICAL THERAPY 159
9.2.1.3.2 OCCUPATIONAL THERAPY 159
9.2.1.3.3 SPEECH THERAPY 159
9.2.1.3.4 OTHERS 159
9.3 DIAGNOSIS 160
9.3.1 IMAGING TEST 161
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 161
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI) 161
9.3.1.3 CAROTID ULTRASOUND 161
9.3.1.4 CEREBRAL ANGIOGRAM 161
9.3.2 BLOOD TEST 161
9.3.3 ECHOCARDIOGRAM 161
9.3.4 LUMBAR PUNCTURE 161
9.3.5 OTHERS 161
10 GLOBAL STROKE MARKET, BY DISTRIBUTION CHANNEL 162
10.1 OVERVIEW 163
10.2 DIRECT 166
10.3 RETAIL 167
10.4 ONLINE 167
11 GLOBAL STROKE MARKET, BY END USER 168
11.1 OVERVIEW 169
11.2 HOSPITALS & CLINICS 172
11.3 SPECIALTY CLINICS 173
11.4 AMBULATORY SURGICAL CENTER 173
11.5 HOMECARE 174
11.6 LABORATORIES 174
11.7 OTHERS 175
12 GLOBAL STROKE MARKET, BY REGION 176
12.1 OVERVIEW 177
12.2 NORTH AMERICA 180
12.2.1 U.S 193
12.2.2 CANADA 204
12.2.3 MEXICO 215
12.3 EUROPE 226
12.3.1 GERMANY 239
12.3.2 U.K. 250
12.3.3 FRANCE 261
12.3.4 ITALY 272
12.3.5 SPAIN 283
12.3.6 RUSSIA 294
12.3.7 NETHERLANDS 304
12.3.8 SWITZERLAND 315
12.3.9 TURKEY 325
12.3.10 AUSTRIA 335
12.3.11 POLAND 346
12.3.12 NORWAY 356
12.3.13 IRELAND 366
12.3.14 REST OF EUROPE 376
12.4 ASIA-PACIFIC 377
12.4.1 CHINA 389
12.4.2 JAPAN 400
12.4.3 INDIA 410
12.4.4 AUSTRALIA 421
12.4.5 SOUTH KOREA 432
12.4.6 SINGAPORE 443
12.4.7 THAILAND 454
12.4.8 PHILIPPINES 465
12.4.9 MALAYSIA 476
12.4.10 INDONESIA 487
12.4.11 VIETNAM 498
12.4.12 TAIWAN 508
12.4.13 REST OF ASIA-PACIFIC 518
12.5 SOUTH AMERICA 519
12.5.1 BRAZIL 531
12.5.2 ARGENTINA 542
12.5.3 CHILE 553
12.5.4 PERU 563
12.5.5 REST OF SOUTH AMERICA 573
12.6 MIDDLE EAST AND AFRICA 574
12.6.1 SOUTH AFRICA 586
12.6.2 SAUDI ARABIA 597
12.6.3 EGYPT 608
12.6.4 U.A.E. 618
12.6.5 ISRAEL 628
12.6.6 KUWAIT 638
13 GLOBAL STROKE MARKET, COMPANY LANDSCAPE 649
13.1 COMPANY SHARE ANALYSIS: GLOBAL 649
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 650
13.3 COMPANY SHARE ANALYSIS: EUROPE 651
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 652
14 SWOT ANALYSIS 653
15 COMPANY PROFILES 654
15.1 BRISTOL-MYERS SQUIBB COMPANY 654
15.1.1 COMPANY SNAPSHOT 654
15.1.2 REVENUE ANALYSIS 655
15.1.3 COMPANY SHARE ANALYSIS 655
15.1.4 PRODUCT PORTFOLIO 655
15.2 F. HOFFMANN-LA ROCHE LTD 657
15.2.1 COMPANY SNAPSHOT 657
15.2.2 REVENUE ANALYSIS 658
15.2.3 COMPANY SHARE ANALYSIS 658
15.2.4 PRODUCT PORTFOLIO 659
15.2.5 RECENT DEVELOPMENT 659
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 660
15.3.1 COMPANY SNAPSHOT 660
15.3.2 COMPANY SHARE ANALYSIS 660
15.3.3 PRODUCT PORTFOLIO 661
15.3.4 RECENT DEVELOPMENT 662
15.4 DAIICHI SANKYO COMPANY, LIMITED 663
15.4.1 COMPANY SNAPSHOT 663
15.4.2 REVENUE ANALYSIS 663
15.4.3 COMPANY SHARE ANALYSIS 664
15.4.4 PRODUCT PORTFOLIO 664
15.4.5 RECENT DEVELOPMENT 665
15.5 SANOFI 666
15.5.1 COMPANY SNAPSHOT 666
15.5.2 REVENUE ANALYSIS 666
15.5.3 COMPANY SHARE ANALYSIS 667
15.5.4 PRODUCT PORTFOLIO 667
15.6 ABBOTT 668
15.6.1 COMPANY SNAPSHOT 668
15.6.2 REVENUE ANALYSIS 668
15.6.3 PRODUCT PORTFOLIO 669
15.6.4 RECENT DEVELOPMENT 669
15.7 AMNEAL PHARMACEUTICALS LLC 671
15.7.1 COMPANY SNAPSHOT 671
15.7.2 REVENUE ANALYSIS 671
15.7.3 PRODUCT PORTFOLIO 672
15.7.4 RECENT DEVELOPMENT 672
15.8 ASTRAZENECA 673
15.8.1 COMPANY SNAPSHOT 673
15.8.2 REVENUE ANALYSIS 673
15.8.3 PRODUCT PORTFOLIO 674
15.8.4 RECENT DEVELOPMENT 674
15.9 BAYER AG 675
15.9.1 COMPANY SNAPSHOT 675
15.9.2 REVENUE ANALYSIS 676
15.9.3 PRODUCT PORTFOLIO 676
15.9.4 RECENT DEVELOPMENT 677
15.10 FRESENIUS SE & CO. KGAA 679
15.10.1 COMPANY SNAPSHOT 679
15.10.2 REVENUE ANALYSIS 679
15.10.3 PRODUCT PORTFOLIO 680
15.10.4 RECENT DEVELOPMENT 680
15.11 GLENMARK PHARMACEUTICALS LTD. 681
15.11.1 COMPANY SNAPSHOT 681
15.11.2 REVENUE ANALYSIS 682
15.11.3 PRODUCT PORTFOLIO 682
15.11.4 RECENT DEVELOPMENT 683
15.12 JOHNSON & JOHNSON SERVICES, INC. 684
15.12.1 COMPANY SNAPSHOT 684
15.12.2 REVENUE ANALYSIS 684
15.12.3 PRODUCT PORTFOLIO 685
15.12.4 RECENT DEVELOPMENT 685
15.13 LUPIN 686
15.13.1 COMPANY SNAPSHOT 686
15.13.2 REVENUE ANALYSIS 687
15.13.3 PRODUCT PORTFOLIO 687
15.13.4 RECENT DEVELOPMENT 688
15.14 MEDTRONIC 689
15.14.1 COMPANY SNAPSHOT 689
15.14.2 REVENUE ANALYSIS 689
15.14.3 PRODUCT PORTFOLIO 690
15.14.4 RECENT DEVELOPMENT 691
15.15 PENUMBRA, INC. 692
15.15.1 COMPANY SNAPSHOT 692
15.15.2 REVENUE ANALYSIS 693
15.15.3 PRODUCT PORTFOLIO 693
15.15.4 RECENT DEVELOPMENT 694
15.16 PFIZER INC. 695
15.16.1 COMPANY SNAPSHOT 695
15.16.2 REVENUE ANALYSIS 696
15.16.3 PRODUCT PORTFOLIO 697
15.16.4 RECENT DEVELOPMENT 697
15.17 SANDOZ AG 698
15.17.1 COMPANY SNAPSHOT 698
15.17.2 REVENUE ANALYSIS 698
15.17.3 PRODUCT PORTFOLIO 699
15.17.4 RECENT DEVELOPMENT 700
15.18 TEVA PHARMACEUTICALS USA, INC. 701
15.18.1 COMPANY SNAPSHOT 701
15.18.2 REVENUE ANALYSIS 701
15.18.3 PRODUCT PORTFOLIO 702
15.18.4 RECENT DEVELOPMENT 703
15.19 VIATRIS INC. 704
15.19.1 COMPANY SNAPSHOT 704
15.19.2 REVENUE ANALYSIS 704
15.19.3 PRODUCT PORTFOLIO 705
15.19.4 RECENT DEVELOPMENT 706
16 QUESTIONNAIRE 707
17 RELATED REPORTS 710
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.